<DOC>
	<DOCNO>NCT02915172</DOCNO>
	<brief_summary>There 2 phase study : Phase 1 ( dose escalation ) Phase 2 ( dose expansion ) . The goal Phase 1 clinical research study find high tolerable dose lenvatinib Xeloda ( capecitabine ) give patient advanced cancer . The goal Phase 2 study learn dose lenvatinib capecitabine find Phase 1 help control advance cancer . The safety drug combination study phase study .</brief_summary>
	<brief_title>Lenvatinib Capecitabine Patients With Advanced Malignancies</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , assign study group base join study . Up 4 group 18 participant enrol Phase 1 study , 28 participant enrol Phase 2 . If participant enrol Phase 1 , dose lenvatinib receive depend join study . The first group participant receive low dose level lenvatinib . Each new group receive high dose lenvatinib group , intolerable side effect see . This continue high tolerable dose lenvatinib find . If participant enrol Phase 2 , receive lenvatinib high dose tolerate Phase 1 . All participant receive dose capecitabine . Study Drug Administration : Each study cycle 21 day . Participant take lenvatinib mouth every day capecitabine mouth 2 time every day . Length Study Participation : Participant may continue take study drug long doctor think best interest . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study end-of-study visit ( describe ) . Study Visits : During Week 2 Cycle 1 : - Participant physical exam . - Blood ( 3 teaspoon ) draw routine test . - If participant enrol Phase 2 , tumor biopsy biomarker test . - If participant enrol Phase 2 , blood ( 2 teaspoon ) drawn biomarker , CTC , cfDNA test . During Week 3 Cycle 1 , blood ( 3 teaspoon ) draw routine test . During Week 1 Cycles 2 beyond : - Participant physical exam . - Blood ( 3 teaspoon ) draw routine test . - If participant enrol Phase 2 , blood ( 2 teaspoon ) drawn biomarker , CTC , cfDNA testing . - If participant become pregnant , blood ( 1 teaspoon ) collect pregnancy test . During Weeks 2 3 Cycles 2 beyond , participant call member study staff ask side effect may . This call last 5-10 minute . During Week 3 Cycle 2 every even-numbered cycle ( Cycles 4 , 6 , 8 , ) , participant CT scan MRI . End-of-Study Visit : After participant 's last dose study drug , end-of-study visit . At visit , follow test procedure perform : - Participant physical exam . - Blood ( 3 teaspoon ) draw routine test . - Participant CT scan MRI check status disease . - If participant become pregnant , blood ( 1 teaspoon ) urine collect pregnancy test . - If participant enrol Phase 2 , blood ( 2 teaspoon ) drawn biomarker , CTC , cfDNA test . This investigational study . Lenvatinib FDA approve commercially available treatment certain type thyroid cancer . Capecitabine FDA approve commercially available treatment certain type breast colorectal cancer . It consider investigational use lenvatinib capecitabine treat advance cancer . The study doctor explain study drug design work . Up 46 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Lip Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Male</mesh_term>
	<mesh_term>Eye Neoplasms</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Cartilage Diseases</mesh_term>
	<mesh_term>Soft Tissue Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Fibrous Tissue</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . Patients histologically and/or cytologically confirm solid tumor resistant / refractory approve therapy curative therapy available . 2 . All previous treatment ( include surgery , radiotherapy systemic antineoplastic therapy ) must complete least three week prior study entry acute toxicity must resolve . 3 . Aged &gt; /= 18 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status score &lt; /= 2 . 5 . Written inform consent prior study specific screen procedure understand patient may withdraw consent time without prejudice . 6 . Willing able comply protocol guideline duration study . 1 . Unstable metastasis central nervous system ( CNS ) . 2 . Any following laboratory parameter : ) hemoglobin &lt; 9 g/dL ( 5.6 mmol/L ) ; b ) neutrophils &lt; 1.5 x 109/L ; c ) platelets &lt; 100 x 109/L ; ) serum bilirubin &gt; 25 Âµmol/L ( 1.5 mg/dL ) ; e ) liver function test value &gt; 3 x upper limit normal ( ULN ) f ) serum creatinine &gt; 1.5 x ULN creatinine clearance &lt; 60 mL/minute 3 . Positive history HIV , active hepatitis B active hepatitis C severe/uncontrolled intercurrent illness infection 4 . Centrally locate nonsmall cell lung cancer squamous cell lung cancer 5 . Clinically significant cardiac impairment unstable ischemic heart disease include myocardial infarction within six month study start 6 . Patients mark Baseline prolongation QT/QTc interval ( QTc interval &gt; 450 msec male &gt; 470 msec female ) use Fridericia method QTc analysis 7 . Bleeding thrombotic disorder , use therapeutic dosage anticoagulant , warfarin . Occasional use NSAIDs antiplatelet agent aspirin , clopidogrel , aggrenox dipyridamole consider exclusionary take &lt; 7 day per 28 day . However , patient require chronic use ( &gt; /=7 day 28 day ) full dose aspirin NSAIDs patient exclude . 8 . Requirement chronic use full dose aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 9 . Poorly control hypertension ( define require change hypertensive regimen within 1 week study entry ) patient diagnose hypertension base repeat blood pressure measurement &gt; 160/90 mmHg Screening 10 . Proteinuria &gt; 1+ urine dipstick test 30 mg/dL 11 . A history gastrointestinal malabsorption undergone surgery require gastrointestinal anastomosis within four week start therapy recover major surgery within three week start therapy 12 . History alcoholism , drug addiction , psychiatric psychological condition , opinion Investigator , would impair study compliance . 13 . Any treatment investigational drug within 30 day start study 14 . Previous treatment E7080 15 . Women pregnant breastfeeding ; woman childbearing potential positive pregnancy test Screening pregnancy test . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception ( include two form contraception , one must barrier method ) opinion Investigator . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 16 . Fertile male female partner willing use contraception whose female partner use adequate contraceptive protection 17 . Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Malignant neoplasm breast</keyword>
	<keyword>Malignant neoplasm bone articular cartilage</keyword>
	<keyword>Malignant neoplasm digestive organ</keyword>
	<keyword>Malignant neoplasm eye brain part central nervous system</keyword>
	<keyword>Malignant neoplasm female genital organ</keyword>
	<keyword>Malignant neoplasms ill-defined secondary unspecified site</keyword>
	<keyword>Malignant neoplasms independent ( primary ) multiple site</keyword>
	<keyword>Malignant neoplasm lip oral cavity pharynx</keyword>
	<keyword>Malignant neoplasm male genital organ</keyword>
	<keyword>Malignant neoplasms mesothelial soft tissue</keyword>
	<keyword>Malignant neoplasms respiratory intrathoracic organ</keyword>
	<keyword>Malignant neoplasm thyroid endocrine gland</keyword>
	<keyword>Malignant neoplasm urinary tract</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>E7080</keyword>
	<keyword>Lenvima</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>